[Sensitivity test of anticancer agents by subrenal capsule assay (SRC assay). II--Determination of tumor sensitivity by percentage inhibition of DNA protein].
Subrenal capsule assay(SRC assay) has been reported to be an effective and rapid method for predicting the tumor sensitivity of individual patients to anti-cancer agents. In order to establish a more objective method of determining sensitivity in SRC assay the DNA content was measured by the schmidt-Thannhauser-Schneider method and the protein content was estimated using Bio-Rad protein assay, after removal of a tumor implanted in the subrenal capsular space of ddY mice. Percentage inhibition of DNA/protein had a high correlation with that of relative increase of tumor weight, although three groups treated with mitomycin-C, 5-fluorouracil and cyclophosphamide indicated different values of tumor sensitivity. From these results, the percentage inhibition of DNA/protein seems to be more objective than microscopic measurement for predicting tumor sensitivity.
Nishiyama
M
M
Noso
Y
Y
Yamaguchi
M
M
Hirabayashi
N
N
Toge
T
T
Niimoto
M
M
Hattori
T
T
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D003114:Colony-Forming Units Assay / Q000379:methods*; D003520:Cyclophosphamide / Q000494:pharmacology; D004273:DNA, Neoplasm / Q000032:analysis*; D005472:Fluorouracil / Q000494:pharmacology; D008297:Male; D051379:Mice; D016685:Mitomycin; D008937:Mitomycins / Q000494:pharmacology; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000032:analysis / Q000473:pathology; D014410:Tumor Stem Cell Assay / Q000379:methods*
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D008937:Mitomycins; D016685:Mitomycin; D003520:Cyclophosphamide; D005472:Fluorouracil